

N.E., Please delete page 1 of the specification and replace it with the substitute page 1 that is appended hereto.

In the specification at page 3, prior to the first line of the paragraph appearing at lines 1-10, please insert the following header for this paragraph:

BRIEF SUMMARY OF THE INVENTION

In the specification at page 5, prior to the first line of the paragraph appearing at lines 4-25, please insert the following header for this paragraph:

DETAILED DESCRIPTION OF THE INVENTION

In the specification at page 7, please delete the header appearing at line 5 and substitute therefor the following header:

BRIEF SUMMARY OF THE DRAWINGS

In the specification at page 8, please delete the paragraph appearing at lines 9-19 and substitute therefor the following paragraph:

EXAMPLES

Methods

Chemicals and Reagents

A1

VEGF₁₆₅ was from PeproTech. Placenta growth factor (PIGF was from R & D Systems. Phorbol-12,13-dibutyrate (PDB) was from Calbiochem-Novabiochem. Histamine was from Sigma Chemical Co. SU5416 was prepared by Tsukuba Research Laboratories, Eisai Co., Tsukuba, Japan. Collagen (Vitrogen 100) was obtained from Imperial Laboratories (Europe). [³²P]Phosphate (10 mCi/ml, carrier free) was from ICN-Flow Laboratories. *Staphylococcus aureus* strain V8 protease (P-6306) was from Sigma.

TENTED PRACTICE

In the Claims:

At page 22 and before claim 1, please delete the header appearing at line 1 and substitute therefor the following header:

WHAT IS CLAIMED IS:

Remarks

By the foregoing amendments, Applicants have amended the international application to provide the priority information as required by 37 C.F.R. § 1.78, to place the specification and claims into proper format for U.S. practice, and to insert the abstract (which contains the same text as that appearing on the face page of the international application as published) into the appropriate